Skip to main content
Log in

EGFR-gerichtete palliativeTherapie mit Panitumumab bei rezidivierten und/oder metastasierten Kopf-Hals-Tumoren

SPECTRUM-Studie

EGFR-targeted palliative therapy with panitumumab in recurrent and/or metastatic head and neck cancer

The SPECTRUM study

  • Journal Club
  • Published:
Der Onkologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Vermorken JB et al (2013) Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol 14:697–710

    Article  PubMed  CAS  Google Scholar 

  2. Vermorken JB et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med(11):1116–1127

    Article  Google Scholar 

Download references

Interessenkonflikt

M. Knödler und C. Mozet geben an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M. Knödler.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Knödler, M., Mozet, C. EGFR-gerichtete palliativeTherapie mit Panitumumab bei rezidivierten und/oder metastasierten Kopf-Hals-Tumoren. Onkologe 19, 1074–1075 (2013). https://doi.org/10.1007/s00761-013-2592-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-013-2592-z

Navigation